Company intelligence / Profile preview

Novalar Pharmaceuticals

San Diego, California, United Statesbiospace.com ↗

Ownership: Private
Development stage: NDA

Overview

Novalar Pharmaceuticals developed OraVerse, a first-in-class agent to reverse the effects of local dental anesthesia. The product received FDA approval and was launched in the U.S. market around 2008. The company completed pivotal studies and an NDA filing for its lead program but is no longer active as an independent entity.

Therapeutic areas: Other
Modalities: Small molecules (notably phentolamine mesylate)
Industry: Biotech

Drug pipeline

1 asset

phentolamine mesylate

NDA

Indications: Local dental anesthesia reversal

Partnerships

No major pharma partnerships publicly disclosed; investors included several prominent venture capital firms

Beyond the preview

Go deeper on Novalar Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novalar Pharmaceuticals.

Explore the full profile